Immunotherapy breaks the first line of treatment of esophageal cancer, and then meets the turning point of treatment.

Esophageal cancer, as a high-risk and high-death cancer, has made very limited progress in treatment over the past decade, and it was not until recent years that immunotherapy was approved for second-line treatment of relapsed localized advanced or metastatic esophageal cancer that a new climate of treatment was ushered in.
at a recent online meeting of the European Society of Oncology (ESMO), immunotherapy was again reported, the first esophageal cancer immunotherapy data released, compared with conventional programs significantly extended the total survival period, so that Chinese esophageal cancer patients and doctors excited.
esophageal cancer treatment has not broken through more than a decade, the first immune dawn esophageal cancer is one of the leading causes of cancer death in China, according to the latest statistics released by the National Cancer Center, in 2015 China's new esophageal cancer patients about 246,000, the death toll of about 188,000, ranked sixth and fourth among all cancers.
challenge of treatment of esophageal cancer, there has been no progress in the past decade or so, the five-year survival rate of local late-stage or metastatic esophageal cancer is only 15% to 20%.
part of the problem is due to late detection of esophageal cancer, about 70% of esophageal cancer patients are in the middle and late stages of treatment, poor physical condition, high tumor load.
other hand, esophageal cancer is heterogeneous and limited treatment options, conventional chemotherapy treatment tolerance is poor, easy to relapse.
In the last two years, immunotherapy inhibitor Paboliju monotherapy has been approved by the FDA and the State Drug Administration for the treatment of patients with previous first-line systemic treatment failure, local late stage or metastatic esophageal squamous cell carcinoma (ESCC) with fully validated testing to assess tumor expression PD-L1 (comprehensive positive score (CPS) of 10).
for newly diagnosed and treated patients, the first-line treatment of esophageal cancer is still blank, there is a huge unsecured demand.
immunotherapy comprehensively surrounds esophageal cancer, first-line long survival of new hope for cancer, first-line treatment mainly refers to the initial treatment plan, the treatment effect is clear, for the body's side effects are small, is the first treatment.
the patient in the initial stage of treatment, better physical condition, is the key period of long-term survival benefits of treatment, the selection of the right first-line treatment options for follow-up treatment also has a more positive impact.
, immunotherapy is undoubtedly a huge success if it advances from second-line treatment to first-line treatment, and will also lead to better treatment options for patients.
the just-concluded European Society of Oncology (ESMO) online conference, the first esophageal cancer immunology first-line treatment data released, breaking the gap in esophageal cancer first-line treatment.
The results of keyNOTE-590, the world's first large-scale Phase III clinical trial for local late stage and metastatic esophageal cancer, showed that Pabliju mono-combination chemotherapy compared to conventional chemotherapy programs, resulting in a population-wide benefit, a significant increase in total survival, a 27% reduction in the risk of disease death, and a controlled safety.
Professor Shen Lin, Vice Dean of The Oncology Hospital of Peking University, said: "Paboli zhu single resistance is the first PD-1 inhibitor to significantly benefit the whole population from the first line of treatment for esophageal cancer, and this result is not surprising, as the immune environment of first-time patients is more immune."
This year ESMO is the big year of esophageal cancer, immunotherapy complements the short board of treatment of esophageal cancer in China, from the second-line adaptation certificate of esophageal cancer to the release of first-line data, research progress is accelerating, I believe these results in the near future will bring great changes to the treatment of esophageal cancer in China.
" in the future, China's esophageal cancer treatment pattern ushered in a new change in China's esophageal cancer and Western esophageal cancer there are large differences, especially in pathological types, about 90% of China's esophageal cancer is esophageal squamous cancer2.
It is precisely because of the differences between esophageal cancer, China's esophageal cancer research started in the 1960s, accumulated a wealth of experience in esophageal cancer prevention and treatment, the urgent need for new treatment to complement the differences between Chinese and Western esophageal cancer short board, to promote the level of diagnosis and treatment of esophageal cancer in China to further improve.
Shen Lin said:
Compared with other cancer species, China's esophageal cancer research has been lagging behind for a long time, in recent years, the success of immunotherapy in esophageal cancer suddenly broke through its bottleneck.
this development, we look forward to having a platform that brings together Chinese multidisciplinary experts and doctors to contribute to the world's esophageal cancer research.
" In this context, in order to promote the national esophageal cancer authority experts and multidisciplinary doctors to explore and exchange, leading China's comprehensive diagnosis and treatment of esophageal cancer into a new stage, the Beijing Society for Cancer Prevention and Control on September 6, 2020 formally established the Beijing Society for The Prevention and Control of Esophageal Cancer Professional Committee, chaired by Professor Shen Lin, and absorbed more than 70 hospitals from the country, including internal medicine, surgery, radiotherapy, imaging, pathology and other disciplines of clinical doctors and basic medical research.
addition of Chinese forces has made clinical trials more diverse and rich, and a number of Pablic pearl monoantigen-related clinical trials have specifically established Chinese subgroups, with positive results from Chinese groups benefiting better than global data.
, especially in the second-line treatment of PD-L1-positive esophageal squamous cancer in China, Paboliju monoantigen can reduce the risk of disease death by 62%, and bring accurate survival improvement to patients with esophageal cancer in China.
KEYNOTE-590 study also included a large number of Chinese esophageal cancer patients and set up a Chinese subgroup, I believe that China's data will still maintain a better advantage than the world, to achieve more amazing new breakthroughs, for esophageal cancer treatment patterns to bring new changes.
immunotherapy has gradually covered the second-line treatment of esophageal cancer to first-line treatment, the future is expected to advance to an earlier stage.
With the popularization of immunotherapy in the application of esophageal cancer and the improvement of the level of diagnosis and treatment of esophageal cancer, I believe that in the near future, the five-year survival rate of esophageal cancer is expected to usher in a significant increase, farewell to the "poor prognosis".
.